S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%
Boston Scientific

BSX Q4 2025 Earnings

Reported Feb 4, 2026 at 6:33 AM ET · SEC Source

Q4 25 EPS

$0.80

BEAT +2.56%

Est. $0.78

Q4 25 Revenue

$5.29B

BEAT +0.04%

Est. $5.28B

vs S&P Since Q4 25

-32.2%

TRAILING MARKET

BSX -27.2% vs S&P +5.0%

Full Year 2025 Results

FY 25 EPS

$3.06

BEAT +0.80%

Est. $3.04

FY 25 Revenue

$20.07B

BEAT +0.01%

Est. $20.07B

Market Reaction

Did BSX Beat Earnings? Q4 2025 Results

Boston Scientific closed out 2025 on a strong note, posting Q4 adjusted EPS of $0.80 against a consensus estimate of $0.78, a 2.56% beat, while revenue of $5.29 billion edged past the $5.28 billion estimate and grew 15.9% year over year. The standout… Read more Boston Scientific closed out 2025 on a strong note, posting Q4 adjusted EPS of $0.80 against a consensus estimate of $0.78, a 2.56% beat, while revenue of $5.29 billion edged past the $5.28 billion estimate and grew 15.9% year over year. The standout driver was the Cardiovascular segment, which expanded 18.2% on a reported basis to $3.48 billion, powered by continued momentum in cardiac ablation and structural heart therapies; the company is also running a clinical trial combining its FARAPULSE and WATCHMAN devices for atrial fibrillation patients, a move that could further entrench its position in cardiac care. Organic growth of 12.7% for the quarter cleared the company's own 11-to-13 percent guidance range, underscoring the breadth of demand across its portfolio. For full year 2025, net sales reached $20.07 billion with adjusted EPS of $3.06. Looking ahead, management guided 2026 reported revenue growth of 10.5 to 11.5 percent and adjusted EPS of $3.43 to $3.49, signaling continued confidence in its diversified medtech platform.

Key Takeaways

  • • Cardiovascular segment grew 18.2% reported and 16.1% organic, driving overall growth
  • • U.S. region grew 17.0% to $3.385 billion, the strongest regional performer
  • • Organic growth of 12.7% exceeded the upper end of company guidance of 11-13%
  • • Adjusted EPS of $0.80 exceeded guidance range of $0.77 to $0.79
24/7 Wall St

BSX YoY Financials

Q4 2025 vs Q4 2024, source: SEC Filings

24/7 Wall St

BSX Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q1 26
24/7 Wall St

BSX Revenue by Geography

With YoY comparisons, source: SEC Filings

Q1 25 Q1 26

“2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals. As a direct result of the dedication, consistency and winning spirit of our team, we have impacted millions of patient lives and are well-positioned to continue on our strong growth trajectory well into the future.”

— Mike Mahoney, Q4 2025 Earnings Press Release

Back to BSX Stock Page